ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology
Link
http://www.nature.com/articles/nmicrobiol2017104.pdf
Reference47 articles.
1. Bush, K. & Jacoby, G. A. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54, 969–976 (2010).
2. Coleman, K. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr. Opin. Microbiol. 14, 550–555 (2011).
3. Bush, K. & Bradford, P. A. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb. Perspect. Med. 6, a025247 (2016).
4. Papp-Wallace, K. M. & Bonomo, R. A. New β-lactamase inhibitors in the clinic. Infect. Dis. Clin. North Am. 30, 441–464 (2016).
5. Poirel, L., Naas, T. & Nordmann, P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob. Agents Chemother. 54, 24–38 (2010).
Cited by 207 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. How to fight bacteria without inducing drug resistance?;Nanotechnology Tools for Infection Control;2025
2. Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex;Expert Review of Anti-infective Therapy;2024-09-08
3. Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review;Infectious Disorders - Drug Targets;2024-09
4. Chances/Challenges of the Role of New Beta-lactamase Inhibitors Against the Growing Threat of NDM-producing Escherichia coli With Penicillin-binding Protein 3 Mutations;Clinical Infectious Diseases;2024-08-23
5. The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections;Current Opinion in Infectious Diseases;2024-08-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3